by admin | Mar 28, 2024 | press-releases
Home PRESS RELEASE CG Oncology to Present Results on Cretostimogene at the AUA 2024 Annual Meeting 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this...
by admin | Feb 27, 2024 | press-releases
Home PRESS RELEASE CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱...
by admin | Jan 30, 2024 | press-releases
Home PRESS RELEASE CG Oncology Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER...
by admin | Jan 24, 2024 | press-releases
Home PRESS RELEASE CG Oncology Announces Pricing of Upsized Initial Public Offering 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to this article now 0:00 📱 MOBILE AUDIO PLAYER =============================== --> Listen to this article now 0:00...
by admin | Dec 5, 2023 | press-releases
Home PRESS RELEASE CG Oncology Receives Both FDA Fast Track and Breakthrough Therapy Designation for Cretostimogene Grenadenorepvec in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen to...
by admin | Nov 30, 2023 | press-releases
Home PRESS RELEASE Cretostimogene Grenadenorepvec Monotherapy First Results Show 75.7% Complete Response Rate at Any Time in Patients With High-Risk BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer 💻 DESKTOP AUDIO PLAYER =============================== --> Listen...